MajorSelective COX-2 inhibitor (coxib)×Calcineurin inhibitor (immunosuppressant)
Updated · Methodology
Mechanism
Tacrolimus can impair renal function on its own. Drugs with known nephrotoxic or neurotoxic effects, including non-steroidal anti-inflammatory drugs (NSAIDs), may potentiate these effects of tacrolimus (tacrolimus summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Etoricoxib is an NSAID. When renal perfusion is compromised, it can reduce renal prostaglandin formation and, as a result, renal blood flow and renal function (etoricoxib SmPC, AEMPS). The combination with etoricoxib has not been studied, but the etoricoxib SmPC states that any NSAID may increase the nephrotoxic effect of tacrolimus (AEMPS). Tacrolimus is more than 98.8% bound to plasma proteins and etoricoxib about 92%. The tacrolimus SmPC asks prescribers to consider possible interactions with other highly protein-bound drugs, including NSAIDs (AEMPS).
Symptoms
Tacrolimus very commonly impairs renal function and commonly causes renal failure, including acute renal failure, and oliguria (tacrolimus summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Acute renal impairment from tacrolimus toxicity can show as high serum creatinine, hyperkalaemia, reduced urea excretion and hyperuricaemia, and is usually reversible (tacrolimus label, US Food and Drug Administration, FDA). With etoricoxib, proteinuria, raised serum creatinine and renal failure are uncommon. Fluid retention, oedema and high blood pressure have been seen in people taking it (etoricoxib SmPC, AEMPS).
Management
The combination is not contraindicated. The tacrolimus summary of product characteristics (SmPC) recommends avoiding tacrolimus with drugs that have known nephrotoxic effects and explicitly lists non-steroidal anti-inflammatory drugs (NSAIDs) among them. Etoricoxib belongs to this class (tacrolimus SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). If the combination cannot be avoided, closely monitor tacrolimus trough blood levels, renal function and other adverse effects. Adjust the tacrolimus dose if needed, and consider reducing it if nephrotoxicity occurs (AEMPS). Monitor renal function when etoricoxib and tacrolimus are used together (etoricoxib SmPC, AEMPS). The US tacrolimus label says to monitor renal function and tacrolimus blood levels when tacrolimus is combined with other known nephrotoxic drugs. During concurrent use, adjust the dose of tacrolimus, the other drug or both (tacrolimus label, US Food and Drug Administration, FDA). Etoricoxib is contraindicated at creatinine clearance below 30 mL/min (etoricoxib SmPC, AEMPS). If renal function worsens during treatment, take appropriate measures and consider stopping etoricoxib (etoricoxib SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica de Prograf 0,5 mg cápsulas duras (tacrolimus) (2026)– AEMPS, CIMA, nº registro 63189, secciones 4.4 y 4.5
- FDA: Prograf (tacrolimus) prescribing information (2025)– Astellas Pharma US. PROGRAF (tacrolimus) capsules, injection, granules. Prescribing information, DailyMed setid 7f667de1-9dfa-4bd6-8ba0-15ee2d78873b, sections 4, 5.11 and 7
- AEMPS: Ficha técnica: Etoricoxib, Arcoxia 120 mg (nº registro 64930), secciones 4.3, 4.4 y 4.5 (2021)– AEMPS, CIMA, nº registro 64930, revisión 05/2021, secciones 4.3, 4.4 y 4.5